Clinical Trials Logo

Filter by:
NCT ID: NCT06432972 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Accelerated Pulmonary Rehabilitation in the Preoperative Period

PREHAB
Start date: January 2, 2024
Phase: N/A
Study type: Interventional

This proposed project will be a single arm, non-masked study. Participants who are actively smoking with a diagnosis of COPD and new lung nodule, either confirmed or suspicious for lung cancer, with a plan for surgical resection will be recruited from the University of Vermont Medical Center (UVMMC) Lung Multidisciplinary Clinic (LMDC). All patients will be enrolled in prehab and offered smoking cessation therapy. The acceptability and feasibility of this intervention will be measured by percent enrollment in study, attendance, barriers to completion, and monitoring of adverse events. The effect of prehab will be measured by traditional metrics, including fitness, respiratory symptoms, and depression scale. Research outcomes will be measured by smoking habits, anxiety, and surgical complications. Investigators estimate that 20 participants over a two-year period will be sufficient to measure the safety and feasibility of this study. Investigators aim to enroll, on average, 2 participants per month in order to complete this study in a timely fashion. Participants will be enrolled in prehab on a rolling basis, as to not delay surgical timeline.

NCT ID: NCT06432959 Recruiting - Depression Clinical Trials

Incorporating Positive Affect Promoting Activities Into Cognitive Behavioral Therapies

PAPA
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

In this study, the investigators will test whether the incorporation of positive affect promoting activities in treatment sessions improves outcomes in the context of CBT for depression and DBT for problems of emotion dysregulation. In clinics focused on each of these treatments, the investigators will evaluate these treatments with and without the addition of positive affect promoting activities.

NCT ID: NCT06432881 Recruiting - Hypoxemia Clinical Trials

Investigation of Skin Pigmentation Effect on Performance of Masimo Pulse Oximetry (INSPIRE)

Start date: December 21, 2023
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate the performance of Masimo RD SET® SpO2 sensors in subjects with light and dark skin pigmentation in the intensive care therapeutic area.

NCT ID: NCT06432868 Recruiting - Muscle Damage Clinical Trials

Solarplast (R) Supplementation Effects Following High-intensity Resistance Exercise

Start date: April 17, 2024
Phase: N/A
Study type: Interventional

The primary goal of this investigation is to assess whether Solarplast (R) supplementation will improve recovery following heavy resistance exercise in active adults. The primary questions to be addressed are: Does Solarplast (R) decrease muscle damage and inflammation associated with heavy resistance exercise? Does Solarplast (R) reduce the decline in performance associate with heavy resistance exercise? Researchers will compare Solarplast (R) to a placebo (a look-alike substance that contains no active ingredients) to see if Solarplast (R) is effective at improving recovery. Participants will be asked to: Take Solarplast (R) or placebo daily for 4 weeks Visit the laboratory at least once per week to receive their supplement Report to the lab for 3 consecutive visits following supplementation to complete a heavy resistance training session and follow-up testing.

NCT ID: NCT06432647 Recruiting - Healthy Volunteers Clinical Trials

A SAD and MAD Study of the Safety, Tolerability, and Pharmacokinetics of ATH-1105

Start date: April 24, 2024
Phase: Phase 1
Study type: Interventional

The goal of this Phase 1 interventional study is to assess the safety, tolerability and pharmacokinetics of ATH-1105 in healthy male and female participants.

NCT ID: NCT06432465 Recruiting - Opioid Use Disorder Clinical Trials

tDCS to Decrease Opioid Relapse (UH3)

Start date: April 17, 2024
Phase: N/A
Study type: Interventional

Investigators will measure behavioral and brain responses following transcranial direct current stimulation (tDCS) to the dorsolateral prefrontal cortex (DLPFC) (anode on right DLPFC, cathode on the left DLPFC) delivered during cognitive control network (CCN) priming. In Phase I, the EEG provided validation of expected changes in these networks following tDCS stimulation of the DLPFC. In this current phase (II), the investigators will perform a larger randomized clinical trial (RCT) (active vs. sham control) to address long-term neurobehavioral outcomes, including opioid relapse, craving, and sustained EEG changes.

NCT ID: NCT06431607 Recruiting - Influenza, Human Clinical Trials

A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults

Start date: May 23, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent vaccine (GSK4382276A) candidate against influenza, administered in healthy younger adults (YA) and older adults (OA).

NCT ID: NCT06431347 Recruiting - Clinical trials for Transplant and Cell Therapy

Prospective Observational Cohort Study of Transplant and Cell Therapy Candidates and Recipients to Assess Social Determinants of Health

Start date: June 17, 2024
Phase:
Study type: Observational

To learn more about social and financial factors that may influence outcomes of TCT treatment at MD Anderson.

NCT ID: NCT06431074 Recruiting - Anxiety Clinical Trials

Radicle Calm 24: A Study of Health and Wellness Products on Feelings of Anxiety and Related Health Outcomes

Start date: May 30, 2024
Phase: N/A
Study type: Interventional

A randomized, double-blind, placebo-controlled study assessing the impact of health and wellness products on feelings of anxiety and related health outcomes

NCT ID: NCT06430788 Recruiting - Aplastic Anemia Clinical Trials

A Study of Emapalumab for Pediatric Aplastic Anemia

Start date: May 21, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out whether upfront emapalumab treatment can help in sAA (Aplastic Anemia) treatment planning and increase the effectiveness of standard treatment options.